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Abstract
Background: Ezatiostat hydrochloride liposomes for injection, a glutathione S-transferase P1-1
inhibitor, was evaluated in myelodysplastic syndrome (MDS). The objectives were to determine the
safety, pharmacokinetics, and hematologic improvement (HI) rate. Phase 1-2a testing of ezatiostat
for the treatment of MDS was conducted in a multidose-escalation, multicenter study. Phase 1
patients received ezatiostat at 5 dose levels (50, 100, 200, 400 and 600 mg/m2) intravenously (IV)
on days 1 to 5 of a 14-day cycle until MDS progression or unacceptable toxicity. In phase 2,
ezatiostat was administered on 2 dose schedules: 600 mg/m2 IV on days 1 to 5 or days 1 to 3 of a
21-day treatment cycle.
Results: 54 patients with histologically confirmed MDS were enrolled. The most common adverse
events were grade 1 or 2, respectively, chills (11%, 9%), back pain (15%, 2%), flushing (19%, 0%),
nausea (15%, 0%), bone pain (6%, 6%), fatigue (0%, 13%), extremity pain (7%, 4%), dyspnea (9%, 4%),
and diarrhea (7%, 4%) related to acute infusional hypersensitivity reactions. The concentration of
the primary active metabolites increased proportionate to ezatiostat dosage. Trilineage responses
were observed in 4 of 16 patients (25%) with trilineage cytopenia. Hematologic Improvement-
Erythroid (HI-E) was observed in 9 of 38 patients (24%), HI-Neutrophil in 11 of 26 patients (42%)
and HI-Platelet in 12 of 24 patients (50%). These responses were accompanied by improvement in
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clinical symptoms and reductions in transfusion requirements. Improvement in bone marrow
maturation and cellularity was also observed.
Conclusion: Phase 2 studies of ezatiostat hydrochloride liposomes for injection in MDS are
supported by the tolerability and HI responses observed. An oral formulation of ezatiostat
hydrochloride tablets is also in phase 2 clinical development.
Trial Registration: Clinicaltrials.gov: NCT00035867
Background
Myelodysplastic syndrome (MDS) is a heterogeneous
group of clonal hematopoietic stem cell disorders charac-
terized by dysplasia in one or more granulocytic, eryth-
roid and megakaryocytic lineages, leading to ineffective
blood cell production and a variable risk of transforming
to acute myeloid leukemia (AML) [1-4]. The treatment
options available to patients with MDS are largely based
on the patient's age and their prognosis as determined by
the International Prognostic Scoring System (IPSS) [5].
For patients in the low to intermediate-1 IPSS risk catego-
ries, the goal of treatment is to improve ineffective hemat-
opoiesis while providing the appropriate supportive care.
In the higher risk patients, the goal is to extend survival
and delay transformation to AML.
Currently, there are 3 U.S. Food and Drug Administration
(FDA) approved treatments for MDS; however, the need
for new targeted therapies with novel mechanisms of
action, such as induction of differentiation and apoptosis
continue to exist. Ezatiostat hydrochloride liposomes for
injection (TLK199), a novel glutathione analog, is cur-
rently being developed for the potential treatment of cyto-
penias associated with MDS or chemotherapy, and
potentially for the treatment of MDS that has transformed
to AML. Ezatiostat is a synthetic tripeptide analog of glu-
tathione that has been shown to stimulate the prolifera-
tion of myeloid precursors [5]. Ezatiostat is metabolized
to TLK117. TLK117 selectively binds to and inhibits glu-
tathione S-transferase P1-1 (GST P1-1), an enzyme that is
overexpressed in many human cancers. Glutathione S-
transferase P1-1 is known to bind to and inhibit Jun-N-
terminal kinase (JNK), a key regulator of cellular prolifer-
Ezatiostat HCl Liposomes for Injection (TLK199) Mechanism of ActionFigure 1
Ezatiostat HCl Liposomes for Injection (TLK199) Mechanism of Action. 1. Esterase action on the diester prodrug, 
ezatiostat liberates the active moiety, the tripeptide diacid; 2. Binding of diacid to GST P1-1 leads to release of JNK; 3. JNK 
phosphorylated c-JUN; 4. Phosphorylated C-Jun translocates to the nucleus and participates in transcription of growth and dif-
ferentiation genes; 5. Trilineage growth and differentiation results.
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ation, differentiation and apoptosis (Figure 1) [6].
TLK117 facilitates dissociation of GST P1-1 from JNK,
leading to activation of JNK and the subsequent promo-
tion of growth and maturation of hematopoietic progeni-
tors in preclinical models (Figure 1), while promoting
apoptosis in human leukemia cell lines. Ezatiostat has
been shown to stimulate the multilineage differentiation
of blasts to mature monocytes, granulocytes and erythro-
cytes with the potential to overcome the block in differen-
tiation (ineffective myelopoiesis) that is characteristic of
MDS [5,7,8]. Mice lacking the gene for GST P1-1, due to
gene deletion, when compared to wild type mice, consist-
ently demonstrate higher than normal neutrophil levels,
in addition to a significant increase in the growth rate of
their embryonal derived fibroblast cells [9]. These results
are consistent with the reports that GST P1-1 is a negative
regulator of cellular growth and differentiation exerting its
effect by binding to JNK [10]. These findings provide the
rationale and scientific support for evaluation of ezatio-
stat in patients with MDS.
Pre-clinical data have shown that ezatiostat was well tol-
erated at single and repeated doses (up to 1920 mg/m2/
day and 3200 mg/m2/day) in rats and dogs, respectively,
with no observed dose-limiting toxicity (DLT). This first-
time-in-human phase 1-2a study of the intravenous (IV)
formulation was designed on the basis of safety demon-
strated in multi-dose toxicology studies and efficacy
reported in animal model studies. The goal of this study
was to determine the maximum tolerated dose (MTD) or
optimal biologic dose (OBD) [as defined as the maximum
therapeutic dose which may occur at doses well below the
MTD], the pharmacokinetics, safety profile and the pre-
liminary evidence of hematologic improvement (HI) in
MDS patients. The results of a phase 1-2a multicenter,
multiple dose-escalation, 2 dose schedules study are
reported here.
Materials and methods
This study was conducted in accordance with Interna-
tional Conference on Harmonization and Good Clinical
Practice standards. Institutional Review Board (IRB)
approval was obtained from all participating institutions.
(Note: authors Azra Raza and Naomi Galili moved to St.
Vincent's Comprehensive Cancer Center, New York, NY,
USA; Natalie Callander moved to University of Wisconsin
Medical Center, Madison, WI; Leonel Ochoa-Bayona
moved to Moffitt Cancer Center, Tampa, FL, USA, and
Peter Curtin moved to University of California, San
Diego, La Jolla, CA, USA; however, these institutions did
not participate in this study.) All patients provided written
informed consent prior to study participation.
Patient population
Patients, age ? 18 years with histologically confirmed
diagnosis of primary MDS with an Eastern Cooperative
Oncology Group (ECOG) performance status of 0 to 2,
were enrolled. Patients were required to have adequate
hepatic and renal function. No prior treatment with
hematopoietic growth factors within 7 days of study entry
and ineligibility for allogeneic bone marrow transplanta-
tion (BMT) were other inclusion criteria. Patients with a
history of allergy to eggs, leptomeningeal metastases or
leukemic meningitis; chemotherapy, radiotherapy or
immunotherapy within 2 weeks of study entry; use of oral
corticosteroids (except for the treatment of new adrenal
failure or hormones for non-MDS related conditions),
and known history of hepatitis B or C, human immuno-
deficiency virus (HIV) infection, or an active infection
requiring antibiotics were excluded.
Study design
This phase 1-2a multicenter, open-label, multidose-esca-
lation study of ezatiostat hydrochloride liposomes for
injection (Telintra®, TLK199) was conducted in patients
with all French-American-British (FAB) classification
types of MDS. The phase 1 objectives of the study were to
evaluate the safety, define the MTD or OBD, and to evalu-
ate the pharmacokinetics of the IV liposomal formulation.
In phase 1, ezatiostat was administered at a starting dose
of 50 mg/m2 followed by subsequent dose-escalation to
levels of 100, 200, 400 and 600 mg/m2 administered daily
at a constant rate infusion over 60 minutes on days 1 to 5
of a 14-day treatment cycle. There are no animal models
for MDS. The phase 1 dose schedule of ezatiostat admin-
istered daily × 5 every 2 weeks was based on the preclinical
animal model of chemotherapy-induced neutropenia. A
minimum of 3 patients were treated at each dose level. At
least 2 patients must have completed 5 days of treatment
and 9 days of follow-up prior to subsequent patients
being enrolled at the next higher dose level. Patients who
did not experience a drug-related toxicity were allowed to
escalate to the next dose level after at least 1 ezatiostat-
naïve patient safely completed the next higher dose level.
If no more than none of 3 or 1 of 6 patients experienced a
DLT, 3 subsequent patients were enrolled at the next
higher dose level. Dose-escalation continued until 2 or
more patients in a cohort experienced a treatment-related
DLT. A hematologic DLT was defined as a grade 4 hema-
tologic toxicity complicated by infection, severe hemor-
rhage or marrow aplasia persisting greater than 4 weeks. A
non-hematologic DLT was defined as any treatment-
related grade 3 or 4 non-hematologic toxicity occurring
during the first treatment cycle.
The MTD was defined as the highest dose at which none
of 3 or 1 of 6 patients experienced a DLT or 1 full dose
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level below the level where a DLT was observed. If bio-
logic activity based on the HI rate was observed prior to
the MTD being established, the OBD would be selected
for phase 2a evaluation. Patients were allowed to continue
treatment until the patient experienced a lack of MDS
response [defined as lack of hematologic improvement
response after receiving 2 cycles of therapy] or unaccepta-
ble toxicities.
The objectives for the phase 2a study were to evaluate
safety, determine the optimal dose schedule, and deter-
mine the objective hematologic improvement response
rate by MDS International Working Group (IWG) (2000)
response criteria. Patients were enrolled sequentially to
the 2 dose schedules that were evaluated: ezatiostat
administered IV at 600 mg/m2 daily on days 1 to 5 or days
1 to 3 of a 21-day treatment cycle. In phase 2a, the 2 dose
schedules were selected to test whether clinical benefit
could be obtained in MDS patients on a more convenient
IV dose schedule(s) to ensure the regimen could be given
as an outpatient. Patients were allowed to continue treat-
ment until MDS progression or unacceptable toxicities. In
both phases of the study, adverse events (AEs) were
graded in accordance with the National Cancer Institute-
Common Toxicity Criteria, version 2.0 (NCI-CTC, v2.0)
[11].
Drug formulation and administration
Ezatiostat hydrochloride liposomes for injection is formu-
lated as a sterile, white lyophilized powder and was recon-
stituted with 0.9% Sodium Chloride for Injection, USP
(United States Pharmacopeia) and diluted in 5% Dextrose
Injection, USP prior to IV administration. Each vial con-
tains 103 mg of active substance (ezatiostat hydrochloride
liposomes for injection); the reconstituted product con-
tains 10 ?g/ml of ezatiostat.
The filtered infusion solution was administered at a con-
stant infusion rate over 60 minutes. Prior to receiving the
first infusion, patients were premedicated with dexameth-
asone, antihistamines and an H2 blocker. If no acute aller-
gic reaction occurred after the first infusion, patients
received subsequent infusions without premedication, at
the investigator's discretion.
Baseline and follow-up assessments
All patients underwent a screening evaluation including a
complete medical history, physical examination with vital
signs, assessment of ECOG performance status, electrocar-
diogram (ECG) and chest X-ray. Pretreatment laboratory
evaluation included complete blood count (CBC) with
differential, reticulocyte count, coagulation profile, serum
chemistry profile, urinalysis and pregnancy test (for
female patients of child-bearing potential only).
Within 72 hours of day 1 of each subsequent treatment
cycle, laboratory tests (CBC with differential and chemis-
try profile), a physical examination including vital signs,
an assessment of ECOG performance status, documenta-
tion of concomitant medication(s) used, and an assess-
ment of AEs were performed and documented. On days 1,
2 and 5 of the first treatment cycle, blood samples for
pharmacokinetic assay of ezatiostat blood levels were
obtained at specified time intervals. Concentrations of
ezatiostat and the active metabolites, TLK236 and
TLK117, were determined in whole blood by an LC-MS
assay. On day 1 in the first treatment cycle, urine samples
were also collected at pre-dose and within 24 hours fol-
lowing the infusion.
Complete blood count with differential were repeated
daily on days 1 to 5 and day 8 of the first treatment cycle
and on days 1, 5 and 8 of subsequent cycles. Hematologic
improvement response assessment by IWG (2000) criteria
was performed during every other treatment cycle and at
the end of study treatment. A formal validated quality of
life instrument was not utilized in this phase 1-2a study;
however, an informal questionnaire was administered at
baseline and on day 1 of each treatment cycle to assess key
MDS clinical symptoms.
In phase 2, on day 1 in the first treatment cycle, patients
underwent a physical examination including vital signs
and an assessment of ECOG performance status, labora-
tory assessments (CBC with differential, reticulocyte
count, chemistry profile and urinalysis), documentation
of concomitant medication(s) used and assessment of
AEs. Vital signs and assessment of AEs were performed on
days 1 to 5 (dose schedule 1) or days 1 to 3 (dose schedule
2) of each subsequent treatment cycle. Hematologic
improvement response assessment by IWG (2000) was
performed every other treatment cycle and at the end of
study treatment.
Dose modifications
Patients who experienced any non-hematologic adverse
event of grade 3 or higher had treatment delayed by up to
a maximum of 3 weeks until recovery to grade 1 or base-
line and continued treatment at a dose reduced by 20%.
Patients who experienced uncomplicated drug-related
grade 4 neutropenia, febrile neutropenia (except uncom-
plicated febrile neutropenia unassociated with grade 3 or
4 infections) and grade 4 thrombocytopenia had treat-
ment reduced by 20% for all subsequent treatments.
For any patient who did not meet the minimum retreat-
ment criteria on day 15 of a treatment cycle in phase 1 or
on day 22 in phase 2a, administration of the subsequent
treatment cycle was delayed and the toxicity was re-evalu-
ated. If recovery did not occur after a delay of 21 days,
Journal of Hematology & Oncology 2009, 2:20 http://www.jhoonline.org/content/2/1/20
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treatment was discontinued and the patient was followed
until resolution of the AE.
Efficacy evaluation
Hematologic improvement response assessment was per-
formed every other treatment cycle and was based on the
standardized criteria for assessing MDS response as pro-
posed by the IWG (2000) for MDS [12,13]. In addition, in
phase 2a, bone marrow assessments were reviewed at 4
months for the natural history assessment per IWG
(2000).
Patients with HI in the erythroid (E), neutrophil (N) and
platelet (P) cell lines were summarized by each individual
cell lineage as HI-E, HI-N and HI-P, respectively, based on
the number of cytopenic peripheral blood cell lineages at
baseline. The primary analysis was conducted under IWG
(2000) criteria.
Ezatiostat hydrochloride liposomes for injection 
pharmacokinetic assessment
Plasma and urinary concentrations of ezatiostat and its
metabolites (TLK235, TLK236 and TLK117) were ana-
lyzed by an LC-MS assay. Limit of quantification (LOQ)
was 10 ?g/ml for all 3 entities. Figure 2 shows the pro-
posed pharmacokinetic model of ezatiostat using non-lin-
ear mixed-effects modeling by NONMEM®.
Statistical analysis
Demographic and baseline MDS disease characteristics of
all treated patients were summarized descriptively. The
sample size and the total number of doses administered
per cycle per patient were summarized overall and for
each dose level of ezatiostat administered IV at 50, 100,
200, 400 and 600 mg/m2.
The incidence of treatment-related AEs and clinically sig-
nificant abnormal changes in laboratory results were sum-
marized by the NCI-CTC v2.0 grades.
Pharmacokinetic data were analyzed with plasma concen-
tration-time profiles constructed for each patient treated
in phase 1. Summary statistics were generated for each
individual and for each treatment group.
Ezatiostat HCl Liposomes for Injection (TLK199) PharmacokineticsFigure 2
Ezatiostat HCl Liposomes for Injection (TLK199) Pharmacokinetics. Formation of metabolites is assumed to be uni-
directional. Ezatiostat undergoes de-esterification to both TLK235 and TLK236; however, because the quantity of TLK235 
measured in this study is consistently less than the level of quantification, this pathway is ignored (dashed lines). TLK236 under-
goes further de-esterification to TLK117. Each of ezatiostat and TLK236 can be eliminated via more than one pathway. How-
ever, this study provides no insight into the fraction of each entity eliminated by each pathway.
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The HI, HI-E, HI-N, and HI-P response rates by IWG
(2000) criteria, were calculated overall and by demo-
graphics and MDS disease characteristics among efficacy-
evaluable patients who received at least 2 cycles of ezatio-
stat. Blood transfusion requirements and clinical symp-
tom improvements were also summarized.
Results
Patient demographic characteristics
Fifty-four patients (35 males and 19 females) with histo-
logically confirmed MDS were enrolled in the study and
treated at 10 centers in the United States between May 13,
2002, and September 27, 2005 (Table 1). Fifty-six percent
of patients had an ECOG performance status of 1 and
65% were male. Ages ranged from 22 to 90 years (median
age was 70 years).
The patients treated in this study exhibited a range of FAB
subtype classifications that was typical for the disease
spectrum of MDS. Thirty (56%) patients had refractory
anemia (RA), 9 (17%) had refractory anemia with ringed
sideroblasts (RARS), 9 (17%) refractory anemia with
excess blasts (RAEB); 3 (6%) with refractory anemia with
excess blasts in transformation (RAEB-t); 1 (2%) chronic
myelomonocytic leukemia (CMML), and 2 (4%) were
unknown. There were no patients with secondary MDS on
this study.
Twenty-seven (50%) patients had an abnormal karyotype.
Trilineage cytopenia was present in 20 patients, bilineage
cytopenia was present in 16 patients, and unilineage cyto-
penia was present in 18 patients.
The median number of prior therapies received by
patients enrolled in this study was 1 (range 0–9) with 29
(54%) having received epoetin, 8 (15%) growth factors
such as G-CSF or 1 (2%) GM-CSF, 4 (7%) lenalidomide or
thalidomide, 2 (4%) azacitidine, 5 (9%) steroids, 3 (6%)
other chemotherapies (e.g., amifostine, interleukin-11,
premaine, investigational drug, Winrho), and 2 (4%) vita-
mins. At baseline, 41 (76%) patients were red blood cell
(RBC) transfusion-dependent by the IWG (2000) criteria.
Ezatiostat hydrochloride liposomes for injection study 
treatment administration
In phase 1, five dose levels ranging from 50 to 600 mg/m2
were evaluated (Table 2). The median number of cycles
received per patient was 4 (range 1–8).
Dose reductions due to AEs were infrequent as only 2
patients required a dose reduction (1 each at the 50 mg/
m2 and 600 mg/m2 dose levels). A total of 13 patients had
dose delays (2 occurring at the 50 mg/m2 dose level, 3 at
100 mg/m2, 1 at 200 mg/m2, 4 at 400 mg/m2 and 3 at the
600 mg/m2 dose level). The dose of ezatiostat was
Table 1: Patient Demographics and MDS Disease Characteristics 
(N = 54)
Age (years)
Median 70
Range 22–90
Age By Decade n (%)
< 60 8 (15)
61 – < 70 19 (35)
70 – < 80 18 (33)
? 80 9 (17)
Gender
Male 35 (65)
Female 19 (35)
Baseline Performance Status (ECOG)
0 18 (33)
1 30 (56)
2 4 (7)
Unknown 2 (4)
Race
Caucasian 48 (88)
Hispanic 3 (6)
Asian 1 (2)
Black 1 (2)
Other 1 (2)
FAB Classification
RA 30 (56)
RARS 9 (17)
RAEB 9 (17)
RAEB-t 3 (6)
CMML 1 (2)
Unknown 2 (4)
Baseline Karyotype
Abnormal 27 (50)
Normal 27 (50)
IPSS Score
Low 39 (72)
Intermediate 1 (2)
High 12 (22)
Unknown 2 (4)
Prior Therapy
Blood Product Support 41 (76)
r-EPO 29 (54)
G-CSF 8 (15)
Steroids 6 (11)
Thalidomide/Lenalidomide 10 (18)
Other Chemotherapy 8 (15)
5-Azacitadine 7 (13)
Vitamins 3 (6)
GM-CSF 1 (2)
Baseline Hematologic Values Median (Range)
ANC 1.4 (0.0–27.3)
HCT 27.0 (19.3–37.8)
Hgb 9.1 (6.7–12.6)
Platelet Count 70.0 (9.0–890)
Abbreviations: RA, refractory anemia; RARS, refractory anemia with 
ringed sideroblasts; RAEB, refractory anemia with excess blasts; 
RAEB-t, refractory anemia with excess blasts in transformation; 
CMML, chronic myelomonocytic leukemia; IPSS, International 
Prognostic Scoring System; r-EPO, recombinant epoetin; G-CSF, 
granulocyte colony-stimulating factor; GM-CSF, granulocyte 
macrophage colony stimulating factor; HCT, hematocrit; Hgb, 
hemoglobin.
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Table 2: Ezatiostat Hydrochloride Liposomes for Injection Treatment Administration
Phase 1
Doase Cohort (mg/m2) # of Patients Total # Cycles Administered Median # of Cycles per Patient (Range)
50 6 16 3 (1–5)
100 3 10 4 (2–4)
200 3 19 7 (4–8)
400 7 36 8 (1–8)
600 7 32 5 (1–8)
TOTAL 26 113 4 (1 – 8)
Phase 2
Treatment (600 mg/m2) # of Patients Total # Cycles Administered Median # of Cycles per Patient (Range)
Dose Schedule 1 10 93 8 (4 – 17)
Dose Schedule 2 18 117 4 (1 – 19)
TOTAL 28 210 7 (1 – 19)
Table 3: Hematologic and Non-Hematologic Adverse Events Related to Ezatiostat in ? 5% of Patients
For All Dose Groups Combined Maximum Toxicity Grade (N = 54)
Adverse Event
(Preferred Term)
Grade 1
n (%)
Grade 2
n (%)
Grade 3
n (%)
Grade 4
n (%)
All Grades
n (%)
Hematologic
Anemia 0 (0) 0 (0) 1 (2) 1 (2) 2 (4)
Leukocytosis 0 (0) 1 (2) 0 (0) 0 (0) 1 (2)
Leukopenia 0 (0) 0 (0) 1 (2) 0 (0) 1 (2)
Thrombocytopenia 0 (0) 1 (2) 0 (0) 0 (0) 1 (2)
Non-hematologic
Chills 6 (11) 5 (9) 0 (0) 0 (0) 11 (20)
Back Pain 8 (15) 1 (2) 0 (0) 1 (2) 10 (19)
Drug Hypersensitivity 4 (7) 1 (2) 3 (6) 2 (4) 10 (19)
Flushing 10 (19) 0 (0) 0 (0) 0 (0) 10 (19)
Nausea 8 (15) 0 (0) 1 (2) 0 (0) 9 (17)
Bone Pain 3 (6) 3 (6) 2 (4) 0 (0) 8 (15)
Dyspnea 5 (9) 2 (4) 0 (0) 0 (0) 7 (13)
Fatigue 0 (0) 7 (13) 0 (0) 0 (0) 7 (13)
Pain in Extremity 4 (7) 2 (4) 1 (2) 0 (0) 7 (13)
Diarrhea 4 (7) 2 (4) 0 (0) 0 (0) 6 (11)
Chest Pain 2 (4) 1 (2) 2 (4) 0 (0) 5 (9)
Dizziness 4 (7) 0 (0) 1 (2) 0 (0) 5 (9)
Chest Discomfort 3 (6) 1 (2) 0 (0) 0 (0) 4 (7)
Headache 3 (6) 1 (2) 0 (0) 0 (0) 4 (7)
Vomiting 4 (7) 0 (0) 0 (0) 0 (0) 4 (7)
Abdominal Pain Upper 2 (4) 1 (2) 0 (0) 0 (0) 3 (6)
Arthralgia 2 (4) 1 (2) 0 (0) 0 (0) 3 (6)
Musculoskeletal Discomfort 3 (6) 0 (0) 0 (0) 0 (0) 3 (6)
Insomnia 2 (4) 1 (2) 0 (0) 0 (0) 3 (6)
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increased from 100 mg/m2 to 200 mg/m2 in the third
treatment cycle in 1 patient, and increased from 200 mg/
m2 to 400 mg/m2 in the fourth treatment cycle in another
patient.
In phase 2a, 10 patients were treated on dose schedule 1
and 18 patients on dose schedule 2. The median number
of treatment cycles received per patient was 8 (range 4–
17) on dose schedule 1 and 4 (range 1–19) on dose sched-
ule 2 for a median of 7 (range 1–19) cycles per patient in
phase 2a. A total of 1345 doses were administered (Table
2).
Safety
Ezatiostat-related hematologic adverse events were
uncommon with 1 patient each (2% each) for grade 4
anemia, grade 3 anemia, grade 3 leukopenia, grade 2 leu-
kocytosis, and grade 2 thrombocytopenia (Table 3).
The most common ezatiostat related non-hematologic
AEs of all grades experienced by ? 10% of the patients (n
= 54) were: chills (20%), drug hypersensitivity (19%),
back pain (19%), flushing (19%), nausea (17%), bone
pain (15%), fatigue (13%), pain in extremity (13%), dys-
pnea (13%), and diarrhea (11%) (Table 3). These events
were mostly grade 1 to grade 2 and were related to acute
infusion hypersensitivity reactions due to the liposomal
formulation, a known side effect of liposomal drugs.
Hypersensitivity reactions to the liposomal formulation
of ezatiostat, in some cases, were ameliorated or pre-
vented by use of a slower infusion rate for ezatiostat and
the prophylactic administration of low-dose dexametha-
sone, antihistamines, and an H2 blocker. No DLTs were
observed.
In phase 1, across all dose levels, a total of 39 serious
adverse events (SAEs) were reported in 14 (54%) patients;
30 SAEs were unrelated to ezatiostat and 9 were ezatiostat
treatment-related (anemia [n = 1], myocardial ischemia [n
= 1], drug hypersensitivity [n = 3], cellulitis [n = 1], bone
pain [n = 2], and pulmonary hemorrhage [n = 1]). In
phase 2a, a total of 14 SAEs were reported in 10 patients
(36%) in both dose schedules combined. Three events
were ezatiostat treatment-related (anaphylactic reaction
[n = 1] and drug hypersensitivity [n = 2]).
In phase 1, treatment with ezatiostat was discontinued
due to AEs in 6 patients: 2 (33%) patients at the 50 mg/
m2 dose level, 2 (27%) patients at the 400 mg/m2 dose
level and 2 (27%) patients at the 600 mg/m2 dose level.
Four (15%) of the discontinuations were considered to be
related to ezatiostat; 2 patients at the 50 mg/m2 dose level,
1 patient at the 400 mg/m2 dose level, and 1 patient at the
600 mg/m2 dose level. In phase 2a, 2 patients (20%) on
dose schedule 1 and 6 patients (33%) on dose schedule 2
were discontinued due to an AE.
No treatment-related deaths were reported in this study.
Of the 12 deaths reported as unrelated to study treatment
in phase 1, five were related to MDS and 6 were due to
other causes. In phase 2a, no deaths were reported in the
cohort on dose schedule 2; however, 2 deaths were
reported in the cohort on dose schedule 1. These deaths
were neither treatment-related nor due to MDS. Overall
treatment-emergent adverse events for the study are
shown in Table 4.
Pharmacokinetics
The pharmacokinetic model for ezatiostat and its metab-
olites (Figure 2) was derived from the concentrations of
ezatiostat and its metabolites in blood of patients admin-
istered intravenous ezatiostat. Ezatiostat undergoes de-
esterification to both TLK235 and TLK236. TLK235 and
TLK236 undergo further de-esterification to TLK117.
Pharmacokinetic parameters were estimated and derived
for TLK199, TLK236 and TLK117. The ezatiostat elimina-
tion half life is 0.20 hours, an AUC/dose of 0.008 hours/
L and a distribution half-life of 0.03 hours. The active
metabolite TLK236 has a half-life of 2.65 hours, with an
AUC/dose of 0.341 hours/L; the metabolite TLK117 has a
half-life of 0.24–0.60 hours with an AUC/dose of 0.0116
hours/L. The data presented fit well with the proposed
pharmacokinetic model. This pharmacokinetic popula-
tion model will be further tested with ongoing patient
data collection and future studies which will further refine
the proposed model of pharmacokinetic parameters of
ezatiostat and its metabolites, TLK236 and TLK177.
Efficacy
Twelve (28%) patients had clinically significant improve-
ment in at least 1 or more cell lineages in efficacy evalua-
ble patients. The longest duration of therapy was 17 cycles
on dose schedule 1 and 19 cycles in dose schedule 2
(Table 2). Clinically significant improvement was
observed across all MDS FAB subtypes and in all blood
cell lineages, including trilineage response in 4 of 16
patients (25%) with 3-cell line cytopenia, bilineage
response in 1 of 13 patients (8%) with 2-cell line cytope-
nia, and unilineage response in 7 of 14 patients (50%)
with single-cell line cytopenia meeting the MDS objective
response criteria for HI (Table 5). Nine of 38 (24%)
patients with low hematocrit/hemoglobin (anemia) had
HI-E, 11 of 26 (42%) patients with WBC/ANC cytopenia
had HI-N, and 12 of 24 (50%) patients with platelet cyto-
penia had HI-P. Patients experienced decreased RBC and
platelet transfusion requirements, and in some cases lead-
ing to transfusion independence.
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Table 4: Overall Hematologic and Non-Hematologic Treatment-Emergent Adverse Events in ? 5% of Patients
For All Dose Groups Combined Maximum Toxicity Grade (N = 54)
Adverse Event
(Preferred Term)
Grade 1
n (%)
Grade 2
n (%)
Grade 3
n (%)
Grade 4
n (%)
Total
n (%)
Hematologic
Anemia 0 (0) 3 (5.6) 11 (20.4) 4 (7.4) 18 (33.3)
Thrombocytopenia 0 (0) 1 (1.9) 2 (3.7) 5 (9.3) 8 (14.8)
Neutropenia 0 (0) 1 (1.9) 1 (1.9) 5 (9.3) 7 (13.0)
Febrile Neutropenia 0 (0) 1 (1.9) 4 (7.4) 0 (0) 5 (9.3)
Leukopenia 0 (0) 0 (0) 2 (3.7) 1 (1.9) 3 (5.6)
Non-Hematologic
Diarrhea 13 (24.1) 6 (11.1) 3 (5.6) 0 (0) 22 (40.7)
Nausea 15 (27.8) 3 (5.6) 1 (1.9) 0 (0) 19 (35.2)
Fatigue 2 (3.7) 14 (25.9) 1 (1.9) 0 (0) 17 (31.5)
Back Pain 11 (20.4) 3 (5.6) 0 (0) 1 (1.9) 15 (27.8)
Bone Pain 6 (11.1) 5 (9.3) 3 (5.6) 0 (0) 14 (25.9)
Headache 10 (18.5) 4 (7.4) 0 (0) 0 (0) 14 (25.9)
Pain in Extremity 9 (16.7) 4 (7.4) 1 (1.9) 0 (0) 14 (25.9)
Chills 7 (13.0) 6 (11.1) 0 (0) 0 (0) 13 (24.1)
Vomiting 11 (20.4) 2 (3.7) 0 (0) 0 (0) 13 (24.1)
Drug Hypersensitivity 5 (9.3) 1 (1.9) 4 (7.4) 2 (3.7) 12 (22.2)
Pyrexia 11 (20.4) 0 (0) 0 (0) 0 (0) 11 (20.4)
Flushing 10 (18.5) 0 (0) 0 (0) 0 (0) 10 (18.5)
Insomnia 7 (13.0) 2 (3.7) 0 (0) 0 (0) 9 (16.7)
Oedema Peripheral 7 (13.0) 2 (3.7) 0 (0) 0 (0) 9 (16.7)
Constipation 3 (5.6) 5 (9.3) 0 (0) 0 (0) 8 (14.8)
Chest Pain 3 (5.6) 2 (3.7) 2 (3.7) 1 (1.9) 8 (14.8)
Cough 5 (9.3) 2 (3.7) 1 (1.9) 0 (0) 8 (14.8)
Dizziness 7 (13.0) 0 (0) 1 (1.9) 0 (0) 8 (14.8)
Dyspnoea 5 (9.3) 2 (3.7) 0 (0) 1 (1.9) 8 (14.8)
Arthralgia 3 (5.6) 3 (5.6) 1 (1.9) 0 (0) 7 (13.0)
Asthenia 4 (7.4) 3 (5.6) 0 (0) 0 (0) 7 (13.0)
Contusion 7 (13.0) 0 (0) 0 (0) 0 (0) 7 (13.0)
Decreased Appetite 4 (7.4) 2 (3.7) 1 (1.9) 0 (0) 7 (13.0)
Dry Mouth 5 (9.3) 1 (1.9) 0 (0) 0 (0) 6 (11.1)
Epistaxis 5 (9.3) 0 (0) 1 (1.9) 0 (0) 6 (11.1)
Tachycardia 5 (9.3) 1 (1.9) 0 (0) 0 (0) 6 (11.1)
Anorexia 3 (5.6) 1 (1.9) 1 (1.9) 0 (0) 5 (9.3)
Chest Discomfort 4 (7.4) 1 (1.9) 0 (0) 0 (0) 5 (9.3)
Dyspepsia 4 (7.4) 1 (1.9) 0 (0) 0 (0) 5 (9.3)
Dyspnoea Exertional 1 (1.9) 4 (7.4) 0 (0) 0 (0) 5 (9.3)
Ecchymosis 5 (9.3) 0 (0) 0 (0) 0 (0) 5 (9.3)
Musculoskeletal Discomfort 5 (9.3) 0 (0) 0 (0) 0 (0) 5 (9.3)
Somnolence 4 (7.4) 0 (0) 1 (1.9) 0 (0) 5 (9.3)
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Discussion
This phase 1-2a study was the first clinical study of ezatio-
stat hydrochloride liposomes for injection in patients
with all FAB classification types of MDS.
In phase 1, patients with MDS were administered ezatio-
stat at doses up to 600 mg/m2 IV daily for 5 days. Adverse
events were generally mild to moderate in grade, with rel-
atively few serious events reported. No DLTs were
observed; therefore, the MTD was not obtained. The opti-
mal biologic dose was determined to be 600 mg/m2 and
was administered on 2 schedules during phase 2a: 600
mg/m2 IV on days 1 to 5 or on days 1 to 3 of a 21-day treat-
ment cycle. Both dose schedules were well tolerated and
hematologic improvement responses were observed on
both schedules.
Hematologic improvement, including bilineage or triline-
age responses, by IWG (2000) criteria was observed across
all FAB subtypes of MDS, IPSS risk and in normal and
abnormal karyotypes. Hematologic improvement was
observed in patients who had failed or progressed follow-
ing a range of prior therapies and supportive care regi-
mens. Reduction of transfusion requirements or
transfusion independence was reported in some cases.
Improvements in bone marrow maturation and cellular-
ity were also observed.
Conclusion
In conclusion, further clinical investigation of ezatiostat
treatment in patients with MDS is supported by the toler-
ability and hematologic improvement responses in all 3
cell lineages seen with intravenous ezatiostat, including
independence or reduction of RBC and platelet transfu-
Urinary Tract Infection 1 (1.9) 4 (7.4) 0 (0) 0 (0) 5 (9.3)
Abdominal Pain Upper 2 (3.7) 2 (3.7) 0 (0) 0 (0) 4 (7.4)
Depression 3 (5.6) 1 (1.9) 0 (0) 0 (0) 4 (7.4)
Dry Skin 4 (7.4) 0 (0) 0 (0) 0 (0) 4 (7.4)
Infusion Site Bruising 4 (7.4) 0 (0) 0 (0) 0 (0) 4 (7.4)
Infusion Site Reaction 3 (5.6) 0 (0) 1 (1.9) 0 (0) 4 (7.4)
Neck Pain 3 (5.6) 0 (0) 1 (1.9) 0 (0) 4 (7.4)
Pneumonia 1 (1.9) 1 (1.9) 2 (3.7) 0 (0) 4 (7.4)
Pruritus 4 (7.4) 0 (0) 0 (0) 0 (0) 4 (7.4)
Rash 4 (7.4) 0 (0) 0 (0) 0 (0) 4 (7.4)
Anxiety 2 (3.7) 1 (1.9) 0 (0) 0 (0) 3 (5.6)
Conjunctival Hemorrhage 3 (5.6) 0 (0) 0 (0) 0 (0) 3 (5.6)
Dehydration 1 (1.9) 0 (0) 1 (1.9) 1 (1.9) 3 (5.6)
Dysgeusia 3 (5.6) 0 (0) 0 (0) 0 (0) 3 (5.6)
Hematuria 2 (3.7) 0 (0) 1 (1.9) 0 (0) 3 (5.6)
Hyperhidrosis 2 (3.7) 0 (0) 1 (1.9) 0 (0) 3 (5.6)
Hypertension 1 (1.9) 2 (3.7) 0 (0) 0 (0) 3 (5.6)
Hypokalemia 2 (3.7) 0 (0) 1 (1.9) 0 (0) 3 (5.6)
Hypotension 1 (1.9) 1 (1.9) 1 (1.9) 0 (0) 3 (5.6)
Infusion Site Erythema 2 (3.7) 1 (1.9) 0 (0) 0 (0) 3 (5.6)
Infusion Site Pain 3 (5.6) 0 (0) 0 (0) 0 (0) 3 (5.6)
Lung Infiltration 1 (1.9) 1 (1.9) 0 (0) 1 (1.9) 3 (5.6)
Mouth Ulceration 3 (5.6) 0 (0) 0 (0) 0 (0) 3 (5.6)
Musculoskeletal Stiffness 2 (3.7) 1 (1.9) 0 (0) 0 (0) 3 (5.6)
Oedema 2 (3.7) 0 (0) 1 (1.9) 0 (0) 3 (5.6)
Pharyngolaryngeal Pain 2 (3.7) 1 (1.9) 0 (0) 0 (0) 3 (5.6)
Upper Respiratory Tract Infection 1 (1.9) 2 (3.7) 0 (0) 0 (0) 3 (5.6)
Vision Blurred 2 (3.7) 1 (1.9) 0 (0) 0 (0) 3 (5.6)
Table 4: Overall Hematologic and Non-Hematologic Treatment-Emergent Adverse Events in ? 5% of Patients (Continued)
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Table 5: Efficacy
Hematologic Improvement Response Rate (IWG 2000)
Baseline Cell-Line Cytopenia n (%)
Trilineage 4/16 (25)
Bilineage 1/13 (8)
Unilineage 7/14 (50)
Hematologic Responses by Cell-Line Cytopenia (IWG 2000)
Number of Patients Major Response
n (%)
Minor Response
n (%)
Total Response
n (%)
HI-E 38 5 (13) 4 (11) 9 (24)
HI-N 26 9 (35) 2 (8) 11 (42)
HI-P 24 4 (17) 8 (33) 12 (50)
Hematologic Improvement (HI) Response by Patient Demographics & MDS Disease Characteristics
HI-E Response
n (%)
HI-N Response
n (%)
HI-P Response
n (%)
Number of Patients (%) 9/38 (24) 11/26 (42) 12/24 (50)
Gender
Female 2/13 (15) 3/8 (38) 3/9 (33)
Male 7/25 (28) 8/18 (44) 9/15 (60)
Baseline FAB
RA 6/20 (30) 5/12 (42) 7/11 (64)
RARS 1/6 (17) 2/4 (50) 1/1 (100)
RAEB 2/8 (25) 4/7 (57) 3/7 (43)
RAEB-t 0/3 (0) 0/3 (0) 0/3 (0)
CMML 0/1 (0) 0 0/1 (0)
Unknown 0 0 1/1 (100)
Baseline Karyotype
Normal 3/20 (15) 6/16 (38) 5/14 (36)
Abnormal 6/18 (33) 5/10 (50) 7/10 (70)
Transfusion Requirements and Clinical Symptoms Improvement (IWG 2000)
Phase 1: Comparison of Decreased Transfusion Requirements and Clinical Symptoms Improvement
All Dose Levels Combined
n (%)
50% Decreased Transfusion Requirements 3/15 (20)
Clinical Symptoms Improvement 7/21 (33)
Phase 2a: Comparison of Decreased Transfusion Requirements and Clinical Symptoms Improvement by Dose Schedule
Dose Schedule 1 Days 1–5 of 21-
Day Treatment Cycle
n (%)
Dose Schedule 2 Days 1–3 of 21-
Day Treatment Cycle
n (%)
Total
n (%)
50% Decreased Transfusion Requirements 1/5 (20) 1/11 (9) 2/16 (13)
Clinical Symptoms Improvement 9/10 (90) 3/12 (25) 12/22 (55)
Abbreviations: RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess blasts; RAEB-t, 
refractory anemia with excess blasts in transformation; CMML, chronic myelomonocytic leukemia; IWG, International Working Group.
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sion requirements. An oral formulation of ezatiostat is
being evaluated in phase 2 studies in MDS.
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